<DOC>
	<DOCNO>NCT02480998</DOCNO>
	<brief_summary>This study evaluate safety , tolerability immunogenicity IL-YANG quadrivalent vaccine versus IL-YANG trivalent vaccine single intramuscular administration healthy Korean male females 19 &lt; 65 year age .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity 'IL-YANG Flu Vaccine Quadrivalent Inj ' Healthy Korean Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy men woman 19 &lt; 65 year age screen Body weight within ±20 % ideal body weight screen Women childbearing potential must negative serum betahCG visit 2 ; agree use proper contraceptive method 1 month vaccination ( start 3 month screen ) , use medication device druginteraction investigational product . Subjects congenital chronic disease consider suitable study screen assessment ( investigator 's opinion , medical history , physical examination , laboratory test , chest Xray , ECG ) conduct later 28 day prior vaccination Subjects give , fully understood , information study , provide voluntary write informed consent participate study comply applicable study requirement Subject know allergy egg , chicken , component investigational product Subjects receive influenza vaccine within last 6 month prior study entry Subjects know suspected infection HAV , HBV , HCV , HIV VDRL Subjects concurrent past history , immune deficiency disease Subject history GuillainBarre syndrome Subject hemophilia thrombocytopenia treat anticoagulant , increased risk serious bleed intramuscular injection Subjects know allergy drug , food latex , history anaphylaxis Subjects acute fever body temperature &gt; 38.0 Cº within 72 hour prior administration investigational product symptom suspect acute disease within 14 day prior administration investigational product Subjects receive another vaccine within 28 day administration investigational product planning receive another vaccine study . Subjects participate another clinical trial within 30 day administration investigational product . Subjects previously receive bloodderived product ( include immunoglobulin ) within last 3 month prior administration Investigational product , schedule receive treatment bloodderived product study Subjects receive , schedule receive , systemic immunosuppressive therapy , radiation therapy highdose steroid therapy within last 6 month prior administration study Subjects history drug abuse within last 6 month prior vaccination , suspect drug abuse Subjects excessive consumption caffeine , alcohol , tobacco Subjects clinically significant medical psychiatric illness investigator 's opinion , suitable study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>